MedPath

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Phase 3
Active, not recruiting
Conditions
Diabetes Type 2
Interventions
Drug: Placebo
Registration Number
NCT06354660
Lead Sponsor
Eli Lilly and Company
Brief Summary

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
480
Inclusion Criteria
  • Have Type 2 Diabetes (T2D)
  • Have HbA1c ≥ 7.0% to ≤ 9.5%
  • Are naïve to insulin therapy and have not used oral or injectable antihyperglycemic (diabetes) medication for at least 90 days prior to screening
  • Are of stable weight for at least 90 days prior to screening
  • Have a Body Mass Index (BMI) ≥ 23.0 kilograms per meter squared (kg/m^2)
Exclusion Criteria
  • Have Type 1 Diabetes (T1D)
  • Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening
  • Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
  • Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
  • Have an estimated glomerular filtration rate (eGFR) <15 milliliters/minute/1.73 meter squared (mL/min/1.73 m^2) as determined by the central laboratory
  • Have a prior or planned surgical treatment for obesity
  • Have New York Heart Association Functional Classification IV congestive heart failure
  • Have had an acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening
  • Have a known clinically significant gastric emptying abnormality
  • Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
  • Have any lifetime history of a suicide attempt
  • Had chronic or acute pancreatitis
  • Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2
  • Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Retatrutide Dose Level 2RetatrutideParticipants will receive retatrutide administered SC.
Retatrutide Dose Level 3RetatrutideParticipants will receive retatrutide administered SC.
PlaceboPlaceboParticipants will receive placebo administered SC.
Retatrutide Dose Level 1RetatrutideParticipants will receive retatrutide administered subcutaneously (SC).
Primary Outcome Measures
NameTimeMethod
Change from Baseline in Hemoglobin A1c (HbA1c) (%)Baseline, Week 40
Secondary Outcome Measures
NameTimeMethod
Percent Change from Baseline in Body WeightBaseline, Week 40
Percentage of Participants Who Achieve Weight Reduction of ≥ 5%Week 40
Change from Baseline in Body WeightBaseline, Week 40
Percentage of Participants Who Achieve HbA1c < 7.0%Week 40
Percentage of Participants Who Achieve HbA1c ≤ 6.5%Week 40
Percentage of Participants Who Achieve HbA1c < 5.7%Week 40
Change from Baseline in Fasting Serum GlucoseBaseline, Week 40
Percentage of Participants Who Achieve Weight Reduction of ≥ 10%Week 40
Percentage of Participants Who Achieve Weight Reduction of ≥ 15%Week 40
Percentage of Participants Who Achieve HbA1c ≤ 6.5% and ≥ 10% Weight ReductionWeek 40
Percent Change from Baseline in TriglyceridesBaseline, Week 40
Percent Change from Baseline in Non- High-Density Lipoprotein (HDL) CholesterolBaseline, Week 40
Change from Baseline in Systolic Blood Pressure (SBP)Baseline, Week 40

Trial Locations

Locations (47)

Scottsdale Clinical Trials

🇺🇸

Scottsdale, Arizona, United States

Tucson Clinical Research Institute

🇺🇸

Tucson, Arizona, United States

San Fernando Valley Health Institute

🇺🇸

Canoga Park, California, United States

Ark Clinical Research

🇺🇸

Long Beach, California, United States

Northeast Research Institute (NERI)

🇺🇸

Fleming Island, Florida, United States

New Horizon Research Center

🇺🇸

Miami, Florida, United States

Ezy Medical Research

🇺🇸

Miami, Florida, United States

Clinical Research of Central Florida

🇺🇸

Winter Haven, Florida, United States

Trinity Research Centers

🇺🇸

Marietta, Georgia, United States

Cotton O'Neil Clinical Research Center

🇺🇸

Topeka, Kansas, United States

NECCR PrimaCare Research

🇺🇸

Fall River, Massachusetts, United States

Clinical Research Professionals

🇺🇸

Chesterfield, Missouri, United States

Boeson Research MSO

🇺🇸

Missoula, Montana, United States

NJ MedCare & NJ Heart

🇺🇸

Linden, New Jersey, United States

Accellacare - Wilmington - 1917 Tradd Court

🇺🇸

Wilmington, North Carolina, United States

Providence Health Partners-Center for Clinical Research

🇺🇸

Dayton, Ohio, United States

Clinical Research of Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

Preferred Primary Care Physicians

🇺🇸

Uniontown, Pennsylvania, United States

Delricht Research - Tobias Gadson Boulevard - Charleston

🇺🇸

Charleston, South Carolina, United States

Lifedoc Research - Lenox Park Drive

🇺🇸

Memphis, Tennessee, United States

Clinical Research Associates Inc

🇺🇸

Nashville, Tennessee, United States

Velocity Clinical Research, Dallas

🇺🇸

Dallas, Texas, United States

Prime Revival Research Institute, LLC

🇺🇸

Flower Mound, Texas, United States

Valley Institute of Research - Fort Worth

🇺🇸

Fort Worth, Texas, United States

Consano Clinical Research, LLC

🇺🇸

Shavano Park, Texas, United States

Texas Valley Clinical Research

🇺🇸

Weslaco, Texas, United States

Manassas Clinical Research Center

🇺🇸

Manassas, Virginia, United States

MultiCare Rockwood Cheney Clinic

🇺🇸

Cheney, Washington, United States

Eastside Research Associates

🇺🇸

Redmond, Washington, United States

All India Institute of Medical Sciences

🇮🇳

Bhubaneswar, Odisha, India

Gujarat Endocrin Pvt Ltd

🇮🇳

Ahmedabad, Gujarat, India

Nirmal Hospital Pvt Ltd.

🇮🇳

Surat, Gujarat, India

Victoria Hospital, Bangalore Medical College And Research Institute

🇮🇳

Bangalore, Karnataka, India

Government Medical College - Kozhikode

🇮🇳

Kozhikode, Kerala, India

Eternal Heart Care Center and Research Institute

🇮🇳

Jaipur, Rajasthan, India

Brij Medical Centre Private Limited

🇮🇳

Kanpur, Uttar Pradesh, India

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

🇲🇽

Mexico City, Distrito Federal, Mexico

Grupo Ollin Care

🇲🇽

Pachuca, Hidalgo, Mexico

Instituto Jalisciense de Investigacion en Diabetes y Obesidad

🇲🇽

Guadalajara, Jalisco, Mexico

Unidad biomedica avanzada monterrey

🇲🇽

Monterrey, Nuevo León, Mexico

Clínica García Flores SC

🇲🇽

Monterrey, Nuevo León, Mexico

Centro de investigación y control metabólico

🇲🇽

San Nicolás de los Garza, Nuevo León, Mexico

Medical Care and Research SA de CV

🇲🇽

Merida, Yucatán, Mexico

EME RED Hospitalaria

🇲🇽

Mérida, Yucatán, Mexico

Arké SMO S.A de C.V

🇲🇽

Veracruz, Mexico

Dorado Medical Complex

🇵🇷

Dorado, Puerto Rico

Ponce Medical School Foundation Inc.

🇵🇷

Ponce, Puerto Rico

© Copyright 2025. All Rights Reserved by MedPath